Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).
about
Glucose-6-phosphatase deficiencyNatural history of hepatocellular adenoma formation in glycogen storage disease type ILiver tumors in children with metabolic disordersInvestigation and management of the hepatic glycogen storage diseasesCurrent Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for DiagnosisStem cell-derived liver cells for drug testing and disease modelingLiver transplantation in glycogen storage disease type IGlycogen storage disease type I and G6Pase-β deficiency: etiology and therapyAdvanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapyDevelopment of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiencyGlycogen storage diseases: new perspectives.Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3.Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis.Quality of life in adult patients with glycogen storage disease type I: results of a multicenter italian study.Glycogen storage disease type Ia in canines: a model for human metabolic and genetic liver diseaseSuppression of gluconeogenic gene expression by LSD1-mediated histone demethylation.Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.Oxidative stress mediates nephropathy in type Ia glycogen storage disease.Does type I truly dominate hepatic glycogen storage diseases in Korea?: a single center studyKey issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesisRecombinant AAV-directed gene therapy for type I glycogen storage diseases.A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study.Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I.Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation.Disordered Eating and Body Esteem Among Individuals with Glycogen Storage Disease.High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.Perioperative management of hemostasis for surgery of benign hepatic adenomas in patients with glycogen storage disease type ia.Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type IaEsophageal Stricture Secondary to Candidiasis in a Child with Glycogen Storage Disease 1b.Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage diseaseGene therapy for type I glycogen storage diseasesIn vivo hepatic lipid quantification using MRS at 7 Tesla in a mouse model of glycogen storage disease type 1aGlycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure.Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type IaGlycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome.
P2860
Q21202870-5448FD82-F265-4998-981B-6E58904DD00CQ24633522-C0A48E80-99EF-4438-A0AD-D35A2674D749Q26770292-40286F4E-14BE-4C3B-82D2-1562F69EE3C4Q26770303-F08FDA33-D738-4991-B88A-CC3A8BDB4BE5Q26781373-36B41C10-CCA9-423F-906A-B15F5142BEA5Q27012605-A05C0305-0E51-4F6E-A043-712829FD2816Q27013712-0038CF96-2246-43D6-B055-9C27CFAB52C3Q28296663-DCEEA3DF-6968-43AB-8FAF-89CB1584B049Q33563689-DE7DBE9A-8CC5-4490-9E62-ECDAF2CFB16AQ33930092-EEBEFB38-C2FC-454A-80DE-53994F744A9EQ34081768-866A02E1-0CCC-4DDF-98AF-117E076B5696Q34098766-BAADB861-33E2-4843-BE70-4014DDD7B5D5Q34131806-334600F7-EB40-4694-844A-4555876CF74FQ34321129-78FD4D60-F310-471D-B01E-6961C332C779Q34422289-76ED6AB4-3DC2-4A6A-B73E-453437149F87Q34521347-BC4F56E3-B855-4C3F-988C-C57904541BEFQ34766859-606754A4-148B-423D-B495-DC679F312C06Q34768395-B582163A-61B3-447A-80B9-5AA3EF44133DQ34807521-D0ACD3F8-4699-4324-9845-338DC7C08337Q34923585-60386AE7-0DD3-4C5F-9C63-5E72B3AB89FDQ35039264-D0B946C9-DBF2-42D5-B0CD-91FA56AB0551Q35078590-99A651D4-2A92-4BE0-AB5A-F50A0BACE2D5Q35121019-BA2ABEB3-C4C9-47DF-9627-EEF413FA59B4Q35183122-F101DA04-699E-46A2-BF2E-E731EA87AA89Q35720799-1B28C969-11BD-47F8-A666-E96DF9E131DCQ35848722-1765ACB2-ED23-474F-98DC-FB0D8D91F211Q36090555-9F96F851-836E-47B4-A9E4-4E049B396F16Q36336550-233B22E2-1F13-4D31-8A9B-64E7F264473DQ36433240-AEFE2B30-ED8A-44C7-BFD5-388111952B74Q36571603-3AC1DB98-88FD-4464-87B2-82900A563C2CQ36695473-5FC101AD-7179-42C6-85E0-7698EFF0DE75Q36717914-8A52234F-A794-46D2-B454-D02639913280Q36768634-59C86C73-2D2A-4A6C-9B7D-9CE4598B4F76Q36777763-A3996D18-042D-4B2C-A530-4E309EA5360AQ36789527-33C51967-4F17-4C43-9589-59927BC25FAAQ36920632-3DE11EEC-DADF-4F67-98EC-2EE1E6E6B1FDQ36944402-02EF6684-CC91-4334-B896-70DD1DD92C43Q37097027-820D535D-4A5F-49CF-BB76-2827294A13BAQ37150574-76C86B4D-4395-412D-A3A3-D19CBB9013B6Q37180852-6F093BBA-2628-4AFC-966A-88E96723E315
P2860
Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@en
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@nl
type
label
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@en
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@nl
prefLabel
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@en
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@nl
P2093
P2860
P356
P1476
Glycogen storage disease type ...... rage Disease Type I (ESGSD I).
@en
P2093
G Peter A Smit
Gepke Visser
James V Leonard
Jan Peter Rake
Kurt Ullrich
Philippe Labrune
P2860
P2888
P304
P356
10.1007/BF02679990
P478
161 Suppl 1
P577
2002-08-22T00:00:00Z